HG106
Based on 2 publication(s) in Google Scholar
HG106 is an effective SLC7A11 inhibitor. HG106 mediates apoptosis by increasing oxidative stress and endoplasmic reticulum stress, and it has antitumor activity.
For research use only. We do not sell to patients.
- Purity : 99.90%
- CAS No.: 928712-10-1
- Formula: C15H13ClN4O2
- Molecular Weight:316.74
-
Storage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) HG106
More-
Flow Cytometry
Biological Activity
Description
IC50 & Target
SLC7A11
In Vitro
HG106 (1.25-10 μM, 3 min) shows a concentration-dependent inhibition of [14C] cystine consumption and glutathione production[1].
HG106 (0.1-100 μM, 72 h) has a stronger cytotoxic effect on KRAS mutant cell lines[1].
HG106 (0-10 μM, 6 h) dose-dependently increases the total ROS levels in A549 cells[1].
HG106 (0-5 μM, 24 h) causes mitochondrial dysfunction and endoplasmic reticulum stress in A549 cells[1].
HG106 (0-10 μM, 72 h) significantly induces apoptosis in KRAS mutant LUAD cells and inhibits colony formation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:H441 KRAS(G12V), HPNE, HPNE/KRAS
-
Concentration:0.1, 1, 10, 100 μM
-
Incubation Time:72 h
-
Result:Inhibited cell proliferation, with greater effects on KRAS mutant cell lines.
-
Cell Line:A549
-
Concentration:0, 1.25, 2.5, 5 μM
-
Incubation Time:24 h
-
Result:Increased activation of ER stress-related markers IRE1α, PERK and GRP78.
-
Cell Line:KRAS mutant LUAD
-
Concentration:0, 1.25, 2.5, 5, 10; 0, 0.5, 1, 2 μM
-
Incubation Time:72 h
-
Result:Did not cause cell autophagy, induced cell apoptosis, and inhibited colony formation.
In Vivo
HG106 (0-4 mg/kg, once a day, intraperitoneal injection, 20 days) inhibits tumor growth in mice in a xenograft model and induces apoptosis by triggering endoplasmic membrane stress[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:A549 mouse transplant model[1]
-
Dosage:0, 1, 2, 4 mg/kg; daily; 26 days
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Inhibited tumor growth and prolonged the inhibition time of tumor growth.
-
Animal Model:LUAD patient-derived xenograft (PDX) models harboring the G12V mutation in KRAS[1]
-
Dosage:0, 1, 2, 4 mg/kg; daily; 20 days
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Inhibited tumor growth, increased ROS generation and TUNEL signal in patient-derived xenografts validated that HG106 triggered endoplasmic membrane stress-induced apoptosis in vivo.
Chemical Information
-
CAS No. 928712-10-1
-
Appearance Solid
-
Molecular Weight 316.74
-
Formula C15H13ClN4O2
-
Color Off-white to light yellow
-
SMILES
O=C(NC1=CC2=NN(C3=CC=C(OC)C=C3)N=C2C=C1)CCl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Control Release
Apoptotic neutrophil membrane-modified nanoparticles promote wound healing by enhancing efferocytotic capacity of dendritic cells. [Abstract]2025 Oct 10:386:114127. PMID: 40816639
HG106 purchased from MedChemExpress. Usage Cited in: J Control Release. 2025 Oct 10:386:114127. [Abstract]
Flow cytometry analysis of HG106 (2.5-10 μM) in promoting BMDCs phagocytosis efficiency in vitro. The results showed that HG106 was effective at promoting BMDCs efferocytosis in vitro, with the highest phagocytic rate observed at a concentration of 5 μM.
-
Cell Chem Biol
Electrochemical sensor toolkit for simultaneous glutamate detection at edge of cleft and peri-soma. [Abstract]2025 Jun 19;32(6):885-898.e11. PMID: 40466640
Solvent & Solubility
In Vitro:
DMSO : 125 mg/mL (394.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (614 KB)
- English - EN (614 KB)
- Français - FR (614 KB)
- Deutsch - DE (614 KB)
- Norwegian - NO (614 KB)
- Español - ES (614 KB)
- Swedish - SV (614 KB)
- Italian - IT (614 KB)
- Korean - KR (614 KB)
- Portuguese - PT (614 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1572 mL | 15.7858 mL | 31.5716 mL | 78.9291 mL |
| 5 mM | 0.6314 mL | 3.1572 mL | 6.3143 mL | 15.7858 mL | |
| 10 mM | 0.3157 mL | 1.5786 mL | 3.1572 mL | 7.8929 mL | |
| 15 mM | 0.2105 mL | 1.0524 mL | 2.1048 mL | 5.2619 mL | |
| 20 mM | 0.1579 mL | 0.7893 mL | 1.5786 mL | 3.9465 mL | |
| 25 mM | 0.1263 mL | 0.6314 mL | 1.2629 mL | 3.1572 mL | |
| 30 mM | 0.1052 mL | 0.5262 mL | 1.0524 mL | 2.6310 mL | |
| 40 mM | 0.0789 mL | 0.3946 mL | 0.7893 mL | 1.9732 mL | |
| 50 mM | 0.0631 mL | 0.3157 mL | 0.6314 mL | 1.5786 mL | |
| 60 mM | 0.0526 mL | 0.2631 mL | 0.5262 mL | 1.3155 mL | |
| 80 mM | 0.0395 mL | 0.1973 mL | 0.3946 mL | 0.9866 mL | |
| 100 mM | 0.0316 mL | 0.1579 mL | 0.3157 mL | 0.7893 mL |